The Ethical Limits of Randomised Controlled Trials

Evidence-based medicine (EBM) has elevated the randomised controlled trial (RCT) to the status of “gold standard” for evaluating the efficacy of medical interventions. While this approach has enabled major advances, it also raises profound ethical questions — particularly in the context of physiological rights.

The Placebo Group Problem

In an RCT, one group of patients receives an active treatment while another receives a placebo. This method is justified when the efficacy of a treatment is genuinely uncertain. But what happens when we already know that a physiological imbalance exists and correction is necessary?

For example: if a person suffers from a measurable vitamin D deficiency, is it ethical to give them a placebo for several months as part of a trial — when we know this deficiency has harmful consequences?

Waiting for Evidence vs Physiological Urgency

EBM typically requires robust evidence before recommending an intervention. This can take years, or even decades, before a treatment is officially validated. During that time, thousands of people suffer from measurable physiological imbalances without access to corrective treatments.

Physiological rights challenge this logic. They hold that when a physiological imbalance is objectively measurable and corrective interventions exist — even if not yet “proven” by RCTs — the individual’s right to receive treatment must prevail.

Towards a Physiological Precautionary Ethics

Rather than waiting for absolute proof, physiological rights advocate a physiological precautionary ethics: in the face of a measurable imbalance, corrective action should be the norm, and inaction must be justified.

This does not mean abandoning scientific rigour, but recognising that human rights cannot be subordinated to the wait for perfect evidence.